Cargando…

Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells

PURPOSE: Chemotherapy for advanced pancreatic cancer has limited efficacy due to the difficultly of treating established tumours and the evolution of tumour resistance. Chemotherapies for pancreatic cancer are typically studied for their cytotoxic properties rather than for their ability to increase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, P. L., Yogaratnam, Y., Samad, M., Kasow, S., Dalgleish, A. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820186/ https://www.ncbi.nlm.nih.gov/pubmed/32661823 http://dx.doi.org/10.1007/s12094-020-02429-0

Ejemplares similares

Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells
por: Gravett, A. M., et al.
Publicado: (2018)

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
por: Liu, W M, et al.
Publicado: (2010)

In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells
por: Gravett, Andrew M., et al.
Publicado: (2019)

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison
por: Sultana, Asma, et al.
Publicado: (2008)

Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy
por: Hamada, T, et al.
Publicado: (2014)

Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy
por: Chen, Yang, et al.
Publicado: (2017)

Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpression
por: Jonckheere, N, et al.
Publicado: (2009)

Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model
por: Humbert, Martine, et al.
Publicado: (2010)

Effects of neoadjuvant FOLFIRINOX and gemcitabine-based chemotherapy on cancer cell survival and death in patients with pancreatic ductal adenocarcinoma
por: Xie, Li, et al.
Publicado: (2019)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
por: Reni, M, et al.
Publicado: (2006)

Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer
por: Principe, Daniel R., et al.
Publicado: (2022)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition
por: IOANNOU, NIKOLAOS, et al.
Publicado: (2016)

Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy
por: Wang, Xiaoguang, et al.
Publicado: (2021)

Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer
por: de Jesus, Victor H. F., et al.
Publicado: (2020)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy
por: Kondo, Shunsuke, et al.
Publicado: (2012)

Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
por: Tang, Yong, et al.
Publicado: (2012)

Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
por: Liu, Xiaoyu, et al.
Publicado: (2016)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy
por: Lu, Huimin, et al.
Publicado: (2019)

Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer
por: Aggarwal, Sahil, et al.
Publicado: (2013)

Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
por: Zhao, Tiansuo, et al.
Publicado: (2014)

OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer
por: Baylot, V, et al.
Publicado: (2011)

Correction: Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
por: Tang, Yong, et al.
Publicado: (2013)

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy
por: Liu, Chen, et al.
Publicado: (2020)

Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study
por: Neri, B, et al.
Publicado: (2002)

Correction: Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
por: Zhao, Tiansuo, et al.
Publicado: (2019)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

The Spectrum of Pulmonary Toxicity in Pancreatic Cancer Patients Receiving Gemcitabine Combination Chemotherapy
por: Baig, Jalal, et al.
Publicado: (2019)

Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells
por: Maietta, Immacolata, et al.
Publicado: (2022)

Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine
por: Yu, Yue, et al.
Publicado: (2019)

Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells
por: Amrutkar, Manoj, et al.
Publicado: (2019)

Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
por: Li, Haorui, et al.
Publicado: (2023)

Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine
por: Huai, Yanyan, et al.
Publicado: (2019)

Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
por: Lu, Jun, et al.
Publicado: (2023)

Immunogenic effects of chemotherapy-induced tumor cell death
por: Wang, Yi-Jun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8oug3rmo4djbep8npm831gpie7